Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
25.21
+0.85 (3.49%)
At close: Oct 7, 2025, 4:00 PM EDT
25.21
0.00 (0.00%)
After-hours: Oct 7, 2025, 4:20 PM EDT
Apellis Pharmaceuticals Revenue
Apellis Pharmaceuticals had revenue of $178.49M in the quarter ending June 30, 2025, a decrease of -10.61%. This brings the company's revenue in the last twelve months to $754.65M, up 20.02% year-over-year. In the year 2024, Apellis Pharmaceuticals had annual revenue of $781.37M with 97.02% growth.
Revenue (ttm)
$754.65M
Revenue Growth
+20.02%
P/S Ratio
4.04
Revenue / Employee
$1,062,886
Employees
710
Market Cap
3.18B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 781.37M | 384.78M | 97.02% |
Dec 31, 2023 | 396.59M | 321.17M | 425.83% |
Dec 31, 2022 | 75.42M | 8.86M | 13.31% |
Dec 31, 2021 | 66.56M | -184.08M | -73.44% |
Dec 31, 2020 | 250.65M | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
APLS News
- 7 days ago - Apellis Pharmaceuticals: Maintaining "Buy" Rating With Continued EMPAVELI Expansions Beyond PNH And C3G-Disorders - Seeking Alpha
- 4 weeks ago - Apellis Pharmaceuticals, Inc. (APLS) Presents At Baird Global Healthcare Conference (Transcript) - Seeking Alpha
- 4 weeks ago - Apellis Pharmaceuticals, Inc. (APLS) Presents At Cantor Global Healthcare Conference 2025 (Transcript) - Seeking Alpha
- 4 weeks ago - Apellis Pharmaceuticals, Inc. (APLS) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript - Seeking Alpha
- 5 weeks ago - Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Apellis Pharmaceuticals: Restart Of Growth Story After Empaveli's New Approval - Seeking Alpha
- 2 months ago - Apellis Pharmaceuticals, Inc. (APLS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Apellis Pharmaceuticals: The Picture Becomes Clearer - Seeking Alpha